Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | PDE4A | P27815 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.67 |
| ▸ | KCNA3 | P22001 | 13/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13920847 | 0.84 | KCNA3 (0.82) | KCNA3 | |
| SCHEMBL13920848 | 0.82 | CYP3A4 (0.81) | ALDH1A1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| Khellin SCHEMBL9655 | 0.81 | CYP3A4 (1.00) | ALDH1A1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| Khellin SCHEMBL30839911 | 0.81 | CYP3A4 (1.00) | ALDH1A1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12132138 | 0.81 | CYP1A1 (0.76) | ALDH1A1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1344680 | 0.79 | CYP3A4 (0.76) | ALDH1A1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12132140 | 0.78 | KCNA3 (0.76) | KCNA3 | |
| SCHEMBL10300860 | 0.78 | CYP3A4 (0.74) | ALDH1A1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1345196 | 0.78 | CYP3A4 (0.74) | ALDH1A1CYP1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13920849 | 0.77 | CYP3A4 (0.81) | ALDH1A1CYP1A1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063093-B2 | Derivatives of 5-(halo)alkanoyl-6-hydroxy- benozofuran, benzothiophene, or indole; autoimmune diseases; systemic lupus erythematosis, rheumatoid arthritis, multiple sclerosis and psoriasis, transplant rejection; antiproliferative, anticarcinogenic, antidiabetic, antiinflammatory and antiulcer agents | HARVEY ANDREW J (AU) | 2011-11-22 | — | — | US | disclosed |
| US-20080221194-A1 | Novel Potassium channel Blockers and Uses Thereof | HARVEY ANDREW J | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221194-A1 | Novel Potassium channel Blockers and Uses Thereof | KCNAB1, KCNB1, KCNMB1 | ALDH1A1 982/4885CYP1A1 1790/4885CYP1A2 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.